The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.
(Bloomberg) -- Teva Pharmaceutical Industries Ltd. won a U.S. Supreme Court patent ruling that will help it forestall generic competition to its top-selling Copaxone multiple- sclerosis drug.
Voting 7-2, the justices gave a reprieve to a Teva patent that would protect Copaxone from rivals until September 2015. The majority told a lower court to reconsider a ruling invalidating the patent.
To contact the reporter on this story: Greg Stohr in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Laurie Asseo at email@example.com